{
    "key_points": [
        "The U.S. FDA approved the first COVID-19 vaccine, Pfizer-BioNTech, now marketed as Comirnaty, for individuals 16 and older.",
        "Comirnaty will continue to be available under emergency use authorization (EUA) for individuals 12 to 15 years and for a third dose in certain immunocompromised individuals.",
        "Acting FDA Commissioner Janet Woodcock, M.D., emphasized the vaccine meets the FDA's high standards for safety, effectiveness, and manufacturing quality.",
        "Since December 11, 2020, the Pfizer-BioNTech COVID-19 Vaccine has been available under EUA for individuals 16 years of age and older.",
        "FDA-approved vaccines undergo rigorous review for quality, safety, and effectiveness.",
        "Comirnaty uses mRNA to train the immune system to react defensively against COVID-19 and does not alter an individual's genetic material.",
        "Peter Marks, M.D., Ph.D., director of FDAâ€™s Center for Biologics Evaluation and Research, assured the public of the thorough evaluation of the vaccine.",
        "Clinical trials showed Comirnaty is 91% effective in preventing COVID-19 disease.",
        "Common side effects include pain at the injection site, fatigue, headache, muscle or joint pain, chills, and fever.",
        "The FDA is requiring postmarketing studies to assess risks of myocarditis and pericarditis and has noted an increased risk of these conditions, especially in males under 40."
    ],
    "spokespersons": [
        "Janet Woodcock, M.D. (Acting FDA Commissioner)",
        "Peter Marks, M.D., Ph.D. (Director of FDA\u2019s Center for Biologics Evaluation and Research)"
    ],
    "article_type": "government agency statement",
    "dateline": "",
    "audience": "general public",
    "stance": "neutral"
}